Parkinson's disease

New England Journal of Medicine

Volumn 339, Issue 15, 1998, Pages 1044-1053

  Lang, Anthony E ^a,b,c   Lozano, Andres M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; PARKINSON DISEASE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW;

CELL DEATH; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; LEWY BODIES; PARKINSON DISEASE;

EID: 0032497504     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199810083391506     Document Type: Review

References (93)

1. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-6.
2. Morens DAM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 1996;46: 1044-50.
3. Louis ED, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson disease. Arch Neurol 1997;54:260-4.
4. Lilienfeld DE, Perl DP. Projected neurodegenerative disease mortality in the United States, 1990-2040. Neuroepidemiology 1993;12:219-28.
5. de Rijk MC, Tzourio C, Breteler MMB, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. J Neurol Neurosurg Psychiatry 1997;62:10-5.
6. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sci 1991;18:275-8.
7. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-8.
8. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994;117:835-45.
9. Ghika J, Bogousslavsky J. Presymptomatic hypertension is a major feature in the diagnosis of progressive supranuclear palsy. Arch Neurol 1997; 54:1104-8.
10. Lang AE, Riley DE, Bergeron C. Cortical-basal ganglionic degeneration. In: Calne DB, ed. Neurodegenerative diseases. Philadelphia: W.B. Saunders, 1994:877-94.
11. Giladi N, Burke RE, Kostic V, et al. Hemiparkinsonism-hemiatrophy syndrome: clinical and neuroradiologic features. Neurology 1990;40:1731-4.
12. Lang AE, Curran T, Provias J, Bergeron C. Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. Can J Neurol Sci 1994;21:311-8. [Erratum, Can J Neurol Sci 1995;22:73-4.]
13. 123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-7.
14. 123I]β-CIT and SPECT: correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50: 9-24.
15. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology 1993;43:Suppl 6:S6-S16.
16. Wolters EC, Huang C-C, Clark C, et al. Positron emission tomography in manganese intoxication. Ann Neurol 1989;26:647-51.
17. 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia. Neurology 1993; 43:1563-8.
18. 123I]-IBZM SPET study. J Neural Transm Suppl 1995; 45:113-22.
19. 11C]raclopride. Mov Disord 1997;12:33-8.
20. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997;42:720-6.
21. 11C]diprenorphine PET study. Brain 1995;118:951-8.
22. 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995;45:1995-2004.
23. Davie CA, Wenning GK, Barker GJ, et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995;37:204-10.
24. Tedeschi G, Litvan I, Bonavita S, et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997;120:1541-52.
25. Ellis CM, Lemmens G, Williams SCR, et al. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology 1997;49:438-44.
26. Davie CA, Pirtosek Z, Barker GJ, Kingsley DPE, Miller PH, Lees AJ. Magnetic resonance spectroscopic study of parkinsonism related to boxing. J Neurol Neurosurg Psychiatry 1995;58:688-91.
27. Mayeux R, Chen J, Mirabello E, et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990;40:1513-7.
28. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol 1996;53:538-42.
29. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-301.
30. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 1988;318:876-80.
31. Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 1994;35:494-8.
32. Gai WP, Blessing WW, Blumbergs PC. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease. Brain 1995;118:1447-59.
33. Gibb WRG, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-96.
34. Huber SJ, Cummings JL. Parkinson's disease: neurobehavioral aspects. New York: Oxford University Press, 1992.
35. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB international workshop. Neurology 1996; 47:1113-24.
36. Churchyard A, Lees AJ. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997;49:1570-6.
37. Braak H, Braak E, Yilmazer D, et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol (Berl) 1994;88:493-500.
38. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease: a community-based study. Arch Neurol 1996;53:175-9.
39. Bergeron C, Petrunka C, Weyer L, Pollanen MS. Altered neurofilament expression does not contribute to Lewy body formation. Am J Pathol 1996;148:267-72.
40. Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993;52:183-91.
41. Trojanowski J, Lee VMY. Phosphorylation of neuronal cytoskeletal proteins in Alzheimer's disease and Lewy body dementias. Ann N Y Acad Sci 1994;747:92-109.
42. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
43. Koller WC, Langston JW, Hubble JP, et al. Does a long preclinical period occur in Parkinson's disease? Neurology 1991;41:Suppl 2:8-13.
44. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988; 24:574-6.
45. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119: 585-91.
46. Calne DB, de la Fuente-Fernández R, Kishore A. Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia. J Neural Transm Suppl 1997;50:47-52.
47. Vingerhoets FJG, Snow BJ, Tetrud JW, Langston JW, Schulzer M, Calne DB. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 1994;36:765-70.
48. Calne DB. Is idiopathic parkinsonism the consequence of an event or a process? Neurology 1994;44:5-10.
49. Burke RE. Programmed cell death and Parkinson's disease. Mov Disord 1998;13:Suppl 1:17-23.
50. Kösel S, Egensperger R, von Eitzen U, Mehraein P, Graeber MB. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol (Berl) 1997;93:105-8.
51. Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 1992;115:33-42.
52. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AHV. Platelet mitochondrial function in Parkinson's disease. Ann Neurol 1992;32: 782-8.
53. Haas RH, Nasirian F, Nakano K, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995;37:714-22.
54. Hirsch EC, Faucheux BA. Iron metabolism and Parkinson's disease. Mov Disord 1998;13:39-45.
55. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47:Suppl 3:S161-S170.
56. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 1998;13:Suppl 1:24-34.
57. Olanow CW. A rationale for using dopamine agonists as a primary symptomatic therapy in Parkinson's disease. In: Olanow CW, Obeso JA, eds. Dopamine agonists in early Parkinson's disease. Royal Tunbridge Wells, England: Wells Medical, 1997:37-48.
58. Rajput AH, Fenton ME, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997;12:634-8.
59. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357-66.
60. Hirsch EC, Mouatt A, Thomasset M, Javoy-Agid F, Agid YA, Graybiel AM. Expression of calbindin D28K-like immunoreactivity in catecholaminergic cell groups of the human midbrain: normal distribution in Parkinson's disease. Neurodegeneration 1992;1:83-93.
61. Lapchak PA, Miller PJ, Jiao SS, Araujo DM, Hilt D, Collins F. Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. Neurodegeneration 1996;5:197-205.
62. Beck KD, Valverde J, Alexi T, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995;373:339-41.
63. Gash DM, Zhang ZM, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996;380:252-5.
64. McGeer EG, McGeer PL. Neurodegeneration and the immune system. In: Calne DB, ed. Neurodegenerative diseases. Philadelphia: W.B. Saunders, 1994:277-99.
65. Zhang Z-X, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993;12:195-208.
66. Moghal S, Rajput AH, D'Arcy C, Rajput R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology 1994;13: 175-8.
67. Jendroska K, Olasode BJ, Daniel SE, et al. Incidental Lewy body disease in black Africans. Lancet 1994;344:882-3.
68. Manyam BV. Paralysis agitans and levodopa in "Ayurveda": ancient Indian medical treatise. Mov Disord 1990;5:47-8.
69. Ben-Shlomo Y. How far are we in understanding the cause of Parkinson's disease? J Neurol Neurosurg Psychiatry 1996;61:4-16.
70. Semchuck KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992;42:1328-35.
71. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995;45:1041-51.
72. Hellenbrand W, Seidler A, Robra BP, et al. Smoking and Parkinson's disease: a case-control study in Germany. Int J Epidemiol 1997;26:328-39.
73. Tzourio C, Rocca WA, Breteler MMB, et al. Smoking and Parkinson's disease: an age-dependent risk effect? Neurology 1997;49:1267-72.
74. de Rijk MC, Breteler MMB, den Breeijen JH, et al. Dietary antioxidants and Parkinson disease: the Rotterdam Study. Arch Neurol 1997;54: 762-5.
75. Wood N. Genes and parkinsonism. J Neurol Neurosurg Psychiatry 1997;62:305-9.
76. Ward CD, Duvoisin RC, Ince S, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983;33:815-24.
77. Tanner CM, Ottman R, Ellenberg JH, et al. Parkinson's disease (PD) concordance in elderly male monozygotic (MZ) and dizygotic (DZ) twins. Neurology 1997;48:Suppl:A333. abstract.
78. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993;43:1173-80.
79. Bandmann O, Marsden CD, Wood NW. Genetic aspects of Parkinson's disease. Mov Disord 1998;13:203-11.
80. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
81. Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 1998;18:106-8.
82. Goedert M. Familial Parkinson's disease: the awakening of α-synuclein. Nature 1997;388:232-3.
83. Chase TN. A gene for Parkinson disease. Arch Neurol 1997;54:1156-7.
84. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997;388:839-40.
85. Scott WK, Staijich JM, Yamaoka LH, et al. Genetic complexity and Parkinson's disease. Science 1997;277:387-8.
86. Gasser T, Müller-Myhsok B, Wszolek ZK, et al. Genetic complexity and Parkinson's disease. Science 1997;277:388-9.
87. Gasser T, Müller-Myhsok B, Wszolek ZK, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998;18:262-5.
88. Riedl AG, Watts PM, Jenner P, Marsden CD. P450 enzymes and Parkinson's disease: the story so far. Mov Disord 1998;13:212-20.
89. Bandmann O, Vaughan J, Holmans P, Marsden CD, Wood NW. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease Lancet 1997;350:1136-9.
90. Schapira AHV. Nuclear and mitochondrial genetics in Parkinson's disease. J Med Genet 1995;32:411-4.
91. Wooten GF, Currie LJ, Bennett JP, Harrison MB, Trugman JM, Parker WD Jr. Maternal inheritance in Parkinson's disease. Ann Neurol 1997;41: 265-8.
92. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996; 40:663-71.
93. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8.